Daily Newsletter

31 October 2023

Daily Newsletter

31 October 2023

Blackstone to acquire majority stake in India’s CARE Hospitals

Blackstone is committing $1bn to the Indian hospital chain, taking over 75% ownership.

October 31 2023

US-based private equity firm Blackstone has forayed into the Indian healthcare market by acquiring a majority stake in Hyderabad-based CARE Hospitals from TPG RISE Funds platform Evercare.

Blackstone is committing $1bn to the Indian hospital chain, taking over a 75% ownership.

Concurrently, CARE Hospitals is set to acquire Kerala-based KIMShealth from private equity firm True North, with True North selling its entire 61% stake in KIMShealth.

This move will result in one of India's largest hospital chains, encompassing 23 hospitals with 4,000 beds across 11 cities, offering advanced care in various medical specialities.

TPG, which has CARE Hospitals’ ownership via its Evercare Health Fund, will retain a minority stake in the combined platform.

While the financial terms were not disclosed, estimates suggest Blackstone's acquisition of CARE Hospitals is valued at over $700m, and the purchase of KIMShealth is around $360m-$420m.

Blackstone private equity managing director Ganesh Mani said: “Life sciences is a key investment theme for Blackstone and we plan to bring in our global scale and operating expertise.”

Blackstone aims to create a patient-centric hospital platform for quality clinical care and services.

It has $1tn in assets under management (AUM).

The company’s focus is on developing businesses that provide enduring value to both institutional and individual investors.

Its portfolio includes over 12,600 real estate assets and more than 230 portfolio companies.

Is the healthcare industry ready to fully embrace the benefits of digitalization and AI?

The healthcare, pharma, and medical devices industries are often risk-averse compared to other sectors when adopting new technologies. However, mainly due to COVID-19, these sectors have witnessed an acceleration in digital transformation. AI can revolutionize the drug discovery process and significantly reduce the time and cost to get a drug to market, particularly in areas of unmet need. There is also huge potential for AI in medical diagnostics. However, using healthcare data for AI development raises data privacy concerns, thereby limiting its adoption.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close